{"id":296382,"date":"2025-06-11T00:00:00","date_gmt":"2025-06-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0007-2024-biopharma-acute-coronary-syndrome-landscape-forecast-disease-landscape-forecast\/"},"modified":"2026-03-31T10:26:02","modified_gmt":"2026-03-31T10:26:02","slug":"dlsfcv0007-2026-biopharma-acute-coronary-syndrome-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0007-2026-biopharma-acute-coronary-syndrome-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Acute Coronary Syndrome &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p class=\"text-align-left\"><span>Acute coronary syndrome<\/span> (<abbr title=\"acute coronary syndrome\">ACS<\/abbr>) encompasses acute ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. <abbr title=\"acute coronary syndrome\">ACS<\/abbr> is a significant cause of morbidity and mortality in developed countries. The therapy market is divided into the acute hospital setting and the post-hospital secondary prevention setting. This report focuses on the 12-month post-hospital secondary prevention market. Oral antiplatelet agents, statins, beta blockers, and angiotensin pathway modulators currently dominate the post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr> market. Despite optimal therapy, the risk of recurrent ischemic events in post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr> patients remains high. The identification of new risk factors and potential targets has created new opportunities to develop drugs that address the limitations of current treatments. Indeed, the forecast period is expected to see the launch of novel lipid-lowering and anti-inflammatory agents to further reduce the risk of cardiovascular events and disease progression.<\/p>\n<p class=\"text-align-left\"><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What factors will drive and constrain the growth of the <abbr title=\"acute coronary syndrome\">ACS<\/abbr> secondary prevention market?<\/li>\n<li>What is the commercial potential of <abbr title=\"lipoprotein\">Lp<\/abbr>(a) inhibitors (pelacarsen, olpasiran, and lepodisiran), the emerging <abbr title=\"proprotein convertase subtilisin\/kexin type 9\">PCSK9<\/abbr> inhibitors (inclisiran [Leqvio], enlicitide), and the <abbr title=\"interleukin\">IL<\/abbr>-6 inhibitor ziltivekimab?<\/li>\n<li>How do leaders in the field of <abbr title=\"acute coronary syndrome\">ACS<\/abbr> management rate the novel therapies targeting <abbr title=\"lipoprotein\">Lp<\/abbr>(a) and inflammation?<\/li>\n<li>To which patients do physicians prescribe the <abbr title=\"proprotein convertase subtilisin\/kexin type 9\">PCSK9<\/abbr> inhibitors? What is their opinion on the future of this class in the secondary prevention of <abbr title=\"acute coronary syndrome\">ACS<\/abbr>?<\/li>\n<\/ul>\n<p class=\"text-align-left\"><strong>Geography<\/strong><\/p>\n<p class=\"text-align-left\">United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p class=\"text-align-left\"><strong>Primary research<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Country-specific interviews with thought-leading cardiologists<\/li>\n<li>Survey data collected for this and other Clarivate research<\/li>\n<\/ul>\n<p class=\"text-align-left\"><strong>Epidemiology<\/strong><\/p>\n<p class=\"text-align-left\">12-month diagnosed prevalent cases of <abbr title=\"acute coronary syndrome\">ACS<\/abbr> by country and subtype<\/p>\n<p class=\"text-align-left\"><strong>Forecast<\/strong><\/p>\n<p class=\"text-align-left\">10-year, annualized, drug-level sales and patient share of key <abbr title=\"acute coronary syndrome\">ACS<\/abbr> secondary prevention therapies through 2034, segmented by brands \/ generics<\/p>\n<p class=\"text-align-left\"><strong>Drug treatments<\/strong><\/p>\n<p class=\"text-align-left\">Coverage of key current and late-phase emerging therapies<\/p>\n<p class=\"text-align-left\"><strong>Product description<\/strong><\/p>\n<p class=\"text-align-left\">Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-296382","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-coronary-syndrome","biopharma-therapy-areas-cardiovascular","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296382\/revisions"}],"predecessor-version":[{"id":575776,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296382\/revisions\/575776"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}